Decisions made by the MHRA following investigations into complaints about advertising for licensed medicines.
Similar Posts
MHRA’s 2024–25 Annual Report and Accounts and Impact Report show progress on safety, innovation, and regulatory excellence
The Medicines and Healthcare products Regulatory Agency (MHRA) has published its 2024–25 Annual Report and Accounts, and accompanying Impact Report.
Isotretinoin: an expert review of suspected psychiatric and sexual side effects
The review of the safety of isotretinoin has concluded.
Research: Digital mental health technology: user and public perspectives on identifying and reporting harms
A research report on attitudes regarding identifying and reporting harms associated with the use of DMHT and awareness of the MHRA Yellow Card Scheme.
Class 4 Medicines Defect Notification: Lexon UK Ltd, Moclobemide 150mg tablets, EL(25)A/50
Lexon UK Ltd has informed the MHRA that the Patient Information Leaflet (PIL) in the cartons for the batches listed in this notification is missing important updated safety information.
Class 4 Medicines Defect Notification: Hikma Farmacêutica, Gemcitabine 2g/52.6ml concentrate for solution for infusion, EL(25)A/43
Hikma Farmacêutica (Portugal) S.A has informed the MHRA that the Patient Information Leaflet (PIL) contained within batch CB0033 of Gemcitabine 2g/52.6ml concentrate for solution for infusion does not contain the side effects of serious skin reactions.
MHRA approves zuranolone to treat postnatal depression in adults following childbirth
As with any medicine, the MHRA will keep the safety of zuranolone under close review.